Psilocybin Lowers Markers of Inflammation and Mitochondrial Stress in Parkinson's Patients

A study shows that psilocybin reduces markers of both inflammation and mitochondrial stress in people diagnosed with Parkinson's disease.

Investigators have spent years examining how psychedelics might address inflammation. Upon entering the brain, the compounds bind to serotonin receptors, a mechanism that has long made them notable candidates for treating mental health conditions.

The implications may reach beyond neurodegenerative illness, potentially applying to neuropsychiatric disorders such as depression and anxiety as well.

Source: Marijuana Moment.